Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the re-investment of dividends paid on January 7, 2010.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transaction prices:
- Ordinary shares purchase price: £12.67 per share.
- Ordinary share ADRs purchase price: $41.13 per ADR.
Material Changes
The filing details an increase in share interests for various executives following the dividend re-investment on January 15, 2010. No material changes to the company's overall financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the specific number of shares and ADRs acquired by each listed director to confirm total holdings.
- Confirm the dividend payment date of January 7, 2010, and the subsequent reinvestment execution date of January 15, 2010.
- Note that this filing does not contain operational or financial performance data for the period.